-+ 0.00%
-+ 0.00%
-+ 0.00%
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Share
Listen to the news

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable
one-year clinical benefit

Global registrational trial to enroll approximately 160 adults with HP to support once-weekly
canvuparatide’s potential as a best-in-class PTH replacement therapy

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending